Rezolute(RZLT) - 2026 Q1 - Quarterly Results

Financial Performance - Cash, cash equivalents, and investments in marketable securities totaled $152.2 million as of September 30, 2025, down from $167.9 million as of June 30, 2025, representing a decrease of approximately 9.9%[7] - The net loss for Q1 fiscal 2026 was $18.2 million, compared to a net loss of $15.4 million for the same period last year, indicating an increase in net loss of about 18.2%[10] - Total operating expenses for Q1 fiscal 2026 were $19.8 million, compared to $16.9 million for the same period in the previous year, representing an increase of approximately 16.9%[15] - The company reported an accumulated deficit of $422.0 million as of September 30, 2025, compared to $403.9 million as of June 30, 2025[15] - Total stockholders' equity decreased to $147.2 million as of September 30, 2025, down from $162.1 million as of June 30, 2025[15] Expenses - Research and development (R&D) expenses increased to $13.1 million for Q1 fiscal 2026, compared to $12.8 million for the same period last year, reflecting an increase of about 2.4%[8] - General and administrative (G&A) expenses rose to $6.7 million for Q1 fiscal 2026, up from $4.2 million in the prior year, marking an increase of approximately 59.5%[9] Clinical Development - The company expects topline results from the Phase 3 sunRIZE trial in congenital hyperinsulinism in December 2025[2] - Enrollment for the streamlined Phase 3 trial for tumor hyperinsulinism is underway, with topline results anticipated in the second half of 2026[6] - The company achieved alignment with the FDA on a streamlined clinical development path for the tumor hyperinsulinism program, reducing the need for a double-blind randomized placebo-controlled trial[6]